Is tirzepatide (Mounjaro) on the PBS in Australia?

No. As of September 2026, tirzepatide is not listed on the Pharmaceutical Benefits Scheme. Eli Lilly rejected PBS listing terms as 'unrealistic and unviable' in April 2026. Patients currently pay the full private cost of tirzepatide in Australia. LillyDirect positions itself as offering 'competitive pricing' compared to other private dispensing channels, but out-of-pocket costs remain a significant access barrier. The separate GLP-1 agonist semaglutide (Ozempic) has a different PBS status for type 2 diabetes; Wegovy (weight management indication) is on PBS for patients meeting specific criteria.

What are the clinical risks of a home-delivery direct dispensing model for GLP-1 medications?

The RACGP's primary concerns are: (1) contraindication risk — a dispensing pharmacist operating via a platform may not have visibility of the patient's full medication list or comorbidity profile, creating drug interaction risk; (2) eating disorder risk — tirzepatide prescribed outside a regular GP-patient relationship may reach patients for whom the medication is clinically inappropriate, including those with active or past eating disorders; and (3) fragmented monitoring — GLP-1 medications can cause significant gastrointestinal side effects, pancreatitis risk, and require metabolic monitoring that is better done within an established GP relationship. Patients should ideally remain under the care of a GP who holds their full medical record.

Eli Lilly launches Mounjaro home delivery. The RACGP has concerns.

This is the model that was always going to arrive. It just arrived today.

Eli Lilly launched LillyDirect in Australia on 22 September 2026, allowing patients with an e-script for tirzepatide (Mounjaro) to have it dispensed by a licensed pharmacist via digital health company Evermed and delivered to their door. The company frames it as improving access and affordability for a medication that is not on the PBS. The RACGP frames it rather differently.

Tirzepatide is a GLP-1/GIP dual agonist. It produces significant weight loss — the SURMOUNT trial found 20–22% body weight reduction at 72 weeks in adults with obesity — and is approved in Australia for chronic weight management, type 2 diabetes, and obstructive sleep apnoea with obesity. It is not cheap. Lilly rejected PBS listing terms in April 2026, calling them “unrealistic and unviable.” The absence of a PBS listing means Australian patients who cannot pay private prices simply do not have access. LillyDirect is pitched as changing the maths on that.

What LillyDirect actually is

The mechanics are not complicated. A patient — or a patient who has been given an e-script by a telehealth GP, a private specialist, or their regular GP — submits that script via the LillyDirect platform. The script is directed to a licensed pharmacist working through Evermed, a digital health dispensing company. The medication is dispensed and home-delivered. Lilly is offering “competitive pricing,” though specific price points were not published at launch.

The model sits within an existing Australian regulatory framework for online dispensing — the pharmacist is licensed, the medication is prescribed. There is nothing in the model itself that bypasses the requirement for a prescription. What it changes is the relationship between the prescriber, the dispensing pharmacist, and the patient’s usual healthcare team.

The RACGP’s concerns, named plainly

RACGP President Dr Michael Wright acknowledged the potential benefit: lower costs “would be good for patients.” His concerns are clinical, not competitive.

The first is contraindication risk. A pharmacist dispensing through a platform has visibility of what the platform knows about a patient’s medications — which may be considerably less than the patient’s regular GP or regular pharmacist knows. GLP-1 medications have contraindications and clinically significant interactions. Tirzepatide is contraindicated with personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. It has relevant interactions with other glucose-lowering agents — hypoglycaemia risk in patients on sulfonylureas or insulin — and requires metabolic monitoring. A dispensing pathway that does not have the full clinical picture creates the conditions for preventable harm.

The second is eating disorders. Dr Wright named this explicitly: “We’ve heard of situations where people with eating disorders have been accessing these medications away from their usual GP… there’s a worry that this new model might create the potential for them to be dispensed away from their usual pharmacist.” Tirzepatide is a powerful medication in a context where body weight and eating are already charged. The absence of an established GP relationship in the dispensing loop means that the screening that should happen before prescribing — a conversation about eating history, body image, psychological wellbeing — is more likely to be missed.

Both sides

The access argument is real. Tirzepatide at private prices is available only to patients who can pay. A model that genuinely reduces the cost of a medication with strong evidence for weight-related cardiometabolic benefit is not inherently bad — it is doing something the PBS system has failed to do. The out-of-pocket costs for obesity pharmacotherapy in Australia are a genuine equity problem, and a company’s competitive pricing initiative, whatever its motivations, may produce some access benefit that the PBS process has not.

The fragmentation concern is also real. The GLP-1 medications are not vitamins. SURMOUNT trial participants were under regular clinical monitoring throughout their treatment. The evidence base that supports tirzepatide’s use comes from structured clinical supervision. Whether that benefit transfers to a patient dispensed without an established GP relationship, without regular metabolic monitoring, and without the safety net of someone who knows their whole clinical picture — that is the question the evidence cannot yet answer, because that is not the context in which the evidence was generated.

The telehealth prescribing ecosystem has already expanded access to these medications beyond the traditional GP-patient relationship. LillyDirect is an extension of a model that is already operating. The RACGP’s concerns about platform-based dispensing are not hypothetical — they are based on patterns already emerging from telehealth prescribing of GLP-1 medications in Australia.

2 cents for general practice

This is a conversation prompt, not a referral pathway. Patients will ask about LillyDirect — some may already have used it. The consultation framing is not “here’s a cheaper way to get Mounjaro.” It is: “I’m glad cost is becoming less of a barrier. Here’s what I need to know about your full medication list and your history before we set you up on tirzepatide, and here’s how we’ll monitor you as we go.”

Ask about eating disorder history before initiating. This is clinical practice for GLP-1 initiation generally — LillyDirect doesn’t change what the clinical standard is. What it does is create a parallel pathway where that conversation may not happen. Being the GP who does the clinical work before prescribing is the right position, regardless of how the medication is eventually dispensed.

Know your patients’ dispensing pathway. A patient who has already sourced tirzepatide via LillyDirect or a similar online platform may not mention it in a consultation about something else. Ask directly about injectable weight loss medications when you are reviewing medications, because the dispensing model has changed the likelihood that the medication is in use without your knowledge.

Lilly’s platform launches today. The clinical questions it raises will not resolve today.

Verdict: maybe — the access benefit is real, the fragmentation risk is real. GPs should be informed of the model and hold the clinical conversation regardless of which pathway dispenses the medication.

Sources cited

Eli Lilly launches Mounjaro home delivery service — newsGP (RACGP), 22 September 2026